CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Be careful when clicking “buy now, pay later”
December 10, 2025
When checking off your holiday lists, it’s hard to keep track of your budget. Sue Heilmayer, executive director of the University of Cincinnati’s Alphaugh Family Economics Center, spoke with Local 12 on the risks of relying on buy now, pay later apps to do your everyday spending.
UC alumna named a 2026 Marshall Scholar
December 10, 2025
The British Government announced the 43 American students who will receive Marshall Scholarships for 2026, including UC alumna Taylor Allgood. The new recipients will begin their graduate studies at leading universities in the United Kingdom next September.
'Sound bulb' research by UC Blue Ash team featured as editor’s pick
December 10, 2025
A research paper on new technology being developed by a professor and students at the University of Cincinnati Blue Ash College is being highlighted as the editor’s pick in a prominent physics journal.